Trial Profile
An open-label, Phase 1 trial assessing safety, tolerability and pharmacokinetics of SAGE-217 in essential tremor patients.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Sep 2016
Price :
$35
*
At a glance
- Drugs Zuranolone (Primary)
- Indications Essential tremor
- Focus Adverse reactions; Pharmacokinetics
- 02 Sep 2016 New trial record